

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Analysis of 3-year invasive disease-free survival from the Phase II PHERGain trial evaluating chemotherapy de-escalation for patients with HER2-positive localized breast cancer indicates that approximately what proportion of patients might safely forgo chemotherapy?
 - a. Half
 - b. One third**
 - c. One quarter

2. Analysis of efficacy and safety results by age presented at ASCO 2023 from the monarchE study of adjuvant abemaciclib combined with endocrine therapy (ET) for patients with ER-positive, HER2-negative, node-positive, high-risk localized breast cancer demonstrated which of the following outcomes?
 - a. Older patients derived less benefit from abemaciclib than did the intent-to-treat (ITT) population
 - b. Older patients derived a similar benefit from abemaciclib in comparison to the ITT population**
 - c. Older patients derived more benefit from abemaciclib than did the ITT population

3. Results from the Phase III NATALEE trial evaluating the addition of ribociclib to ET as adjuvant treatment for patients with ER-positive, HER2-negative localized breast cancer demonstrated a statistically significant improvement in which of the following endpoints with ribociclib?
 - a. Distant disease-free survival**
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b

4. Analysis from the PALMIRA study for patients with ER-positive, HER2-negative advanced breast cancer demonstrated that maintaining palbociclib with a second-line ET after disease progression on prior palbociclib-based therapy did or did not significantly improve progression-free survival in comparison to second-line ET alone?
 - a. Did
 - b. Did not**

5. Final overall survival analysis from the Phase III TROPiCS-02 study of sacituzumab govitecan for patients with ER-positive, HER2-negative metastatic breast cancer demonstrated significant benefit in which of the following endpoints with longer follow-up?
 - a. Progression-free survival
 - b. Overall survival
 - c. Both a and b**
 - d. Neither a nor b